M&A / Deals Jeito Capital secures over $1.2bn for new biopharma investments Pharmaceutical Business ReviewThe milestone increases Jeito's assets under management to 1.6bn, following the 534m closure of Jeito I in 2021.M&A / DealsRead full story pharminent April 9, 2026 (Last updated: April 9, 2026) Pharmaceutical Business Review The milestone increases Jeito’s assets under management to 1.6bn, following the 534m closure of Jeito I in 2021. M&A / DealsRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: FDA seeks permanent future for rare pediatric priority review vouchersNext: EverSea Medicines to acquire Hasten Biopharmaceuticals Related Stories M&A / Deals Teva and Polpharma Biologics sign global deal for ocrelizumab biosimilar pharminent July 10, 2026 M&A / Deals GSK ends dementia alliance with Alector after setbacks pharminent July 9, 2026 M&A / Deals AstraZeneca, GSK intensify China ties with Sino Biopharm deals pharminent July 8, 2026
